Quercetin ( DrugBank: Quercetin )
5 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 84 | Sarcoidosis | 1 |
| 85 | Idiopathic interstitial pneumonia | 1 |
| 192 | Cockayne syndrome | 1 |
| 285 | Fanconi anemia | 2 |
| 299 | Cystic fibrosis | 1 |
84. Sarcoidosis
Clinical trials : 149 / Drugs : 227 - (DrugBank : 81) / Drug target genes : 82 - Drug target pathways : 167
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00402623 (ClinicalTrials.gov) | January 2006 | 20/11/2006 | The Effect of Quercetin in Sarcoidosis | The Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in Sarcoidosis | Sarcoidosis | Dietary Supplement: quercetin;Other: placebo | Maastricht University Medical Center | ZonMw: The Netherlands Organisation for Health Research and Development | Completed | N/A | N/A | All | 18 | N/A | Netherlands |
85. Idiopathic interstitial pneumonia
Clinical trials : 598 / Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02874989 (ClinicalTrials.gov) | December 16, 2016 | 17/8/2016 | Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial | Targeted Removal of Pro-Inflammatory Cells: An Open Label Human Pilot Study in Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) | Drug: Dasatinib + Quercetin;Drug: Placebo | Wake Forest University Health Sciences | Mayo Clinic;The University of Texas Health Science Center at San Antonio | Completed | 50 Years | N/A | All | 26 | Phase 1 | United States |
192. Cockayne syndrome
Clinical trials : 4 / Drugs : 7 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathways : 51
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1900026719 | 2019-11-01 | 2019-10-19 | Clinical study for combined application of vitamin C and quercetin in the treatment of Cockayne's syndrome | Clinical study for combined application of vitamin C and quercetin in the treatment of Cockayne's syndrome | Cockayne's syndrome | test group:Vitamin C and Quercetin; | The First Medical Center of PLA General Hospital | NULL | Pending | 6 | 13 | Both | test group:20; | China |
285. Fanconi anemia
Clinical trials : 59 / Drugs : 118 - (DrugBank : 32) / Drug target genes : 31 - Drug target pathways : 155
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03476330 (ClinicalTrials.gov) | May 8, 2018 | 19/3/2018 | Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia | Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia | Fanconi Anemia;Squamous Cell Carcinoma | Drug: Quercetin (dietary supplement) | Children's Hospital Medical Center, Cincinnati | NULL | Recruiting | 2 Years | N/A | All | 55 | Phase 2 | United States |
| 2 | NCT01720147 (ClinicalTrials.gov) | July 2012 | 25/7/2012 | Quercetin in Children With Fanconi Anemia; a Pilot Study | Quercetin in Children With Fanconi Anemia; a Pilot Study | Fanconi Anemia | Drug: Quercetin (dietary supplement) | Children's Hospital Medical Center, Cincinnati | Food and Drug Administration (FDA) | Recruiting | N/A | N/A | All | 32 | Phase 1 | United States |
299. Cystic fibrosis
Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01348204 (ClinicalTrials.gov) | March 2010 | 1/6/2010 | Nasal Potential Studies Utilizing Cystic Fibrosis Transmembrane Regulator (CFTR) Modulators | Nasal Potential Studies Utilizing CFTR Modulators (UAB Center for Clinical and Translational Science) | Cystic Fibrosis | Other: quercetin | University of Alabama at Birmingham | National Institutes of Health (NIH) | Completed | 8 Years | 65 Years | Both | 32 | Phase 2 | United States |